Article

ISTA submits NDA for once-a-day bromfenac

ISTA Pharmaceuticals Inc. has submitted a new drug application (NDA) to the FDA for its once-a-day formulation of bromfenac sodium ophthalmic solution (Xibrom QD).

Irvine, CA-ISTA Pharmaceuticals Inc. has submitted a new drug application (NDA) to the FDA for its once-a-day formulation of bromfenac sodium ophthalmic solution (Xibrom QD). The company is seeking approval for the drug as a treatment for inflammation, pain, and photophobia following cataract surgery.

The 0.09%, twice-daily formulation of bromfenac, a topical non-steroidal anti-inflammatory (NSAID), was approved in 2005 as the first and only FDA-approved twice-daily NSAID for this indication. It was the fastest-growing ophthalmic product in 2007, according to IMS data. The once-daily formulation contains a higher concentration of the drug.

The twice-a-day drug, under a different trade name but identical formulation, was launched in Japan in 2000 by Senju Pharmaceuticals Co. Ltd. ISTA acquired U.S. marketing rights for the drug in 2002 and launched the product in the United States in 2005.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.